News

Gene therapy appears to be a promising approach for a subset of genetic deafness, although challenges remain with development ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
The primary safety risks associated with gene therapy include immune reactions and off-target effects in unintended organs, such as the liver, lungs, and spleen. Nevertheless, Ali and Townsend note ...
Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...
For nearly three decades, Mayo Clinic researcher Christopher Evans, Ph.D., has pushed to expand gene therapy beyond its ...
The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients ...
If successful, the access model for sickle cell disease gene therapies could serve as a blueprint for other such treatments ...
Findings from St. Jude Children's Research Hospital demonstrate that virtual memory T cells, a specialized group of immune ...